The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
In a real-world observational analysis, belantamab mafodotin demonstrated clinical activity for patients with heavily pretreated relapsed/refractory multiple myeloma.
In a real-world observational analysis, belantamab mafodotin demonstrated clinical activity for patients with heavily pretreated relapsed/refractory multiple myeloma.
The European Commission has approved ibrutinib combined with chemoimmunotherapy for the treatment of mantle cell lymphoma based on results from the phase 3 TRIANGLE clinical trial which demonstrated superior survival outcomes compared with...
The European Commission has approved ibrutinib combined with chemoimmunotherapy for the treatment of mantle cell lymphoma based on results from the phase 3 TRIANGLE clinical trial which demonstrated superior survival outcomes compared with...
For patients with high-risk smoldering multiple myeloma, fixed-duration daratumumab has been approved by the European Commission based on results from the AQUILA phase 3 clinical trial.
For patients with high-risk smoldering multiple myeloma, fixed-duration daratumumab has been approved by the European Commission based on results from the AQUILA phase 3 clinical trial.
Among elderly patients with AML, DNMT3A and TET2 mutations are associated with worse survival outcomes, while IDH1/IDH2 mutations are associated with improved survival, though these mutations were not found to significantly influence choice...
Among elderly patients with AML, DNMT3A and TET2 mutations are associated with worse survival outcomes, while IDH1/IDH2 mutations are associated with improved survival, though these mutations were not found to significantly influence choice...
A regimen of bortezomib and dexamethasone plus pomalidomide demonstrated superior survival outcomes and responses among patients with first-relapsed multiple myeloma, compared with bortezomib and dexamethasone alone.
A regimen of bortezomib and dexamethasone plus pomalidomide demonstrated superior survival outcomes and responses among patients with first-relapsed multiple myeloma, compared with bortezomib and dexamethasone alone.
The small-molecular BET inhibitor, INCB057643, demonstrated clinical activity and manageable safety among patients with relapsed/refractory myelofibrosis.
The small-molecular BET inhibitor, INCB057643, demonstrated clinical activity and manageable safety among patients with relapsed/refractory myelofibrosis.
James B. Bussel, MD, gives an overview of what to expect at the brand new Non-Malignant Hematology Workshop and how the content is critical for hematology and oncology practice.
James B. Bussel, MD, gives an overview of what to expect at the brand new Non-Malignant Hematology Workshop and how the content is critical for hematology and oncology practice.
